Clinical ink has relaunched and expanded a contract research organisation (CRO) partnership programme to enhance subject data collection in clinical trials.
The programme is intended to provide a distinguished trial experience to the company’s partners, as well as its joint sponsor customers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will guarantee a streamlined trial design, functional standards, and the deployment of fit-for-purpose technologies to carry out best-in-class patient data collection in trials.
Clinical ink chief commercial officer Chris Crucitti said: “We are thrilled to provide this exclusive programme to our most valued CRO partners, both current and future.
“Together, we will chart successful growth, powering patient outcomes by providing sponsors not only the most competitive, technologically-advanced eSource, patient data and DCT offering in the market, but also best-in-class operational efficiencies and process optimisation to ensure continual, collective advancement.”
The company has several sponsor associations and trials deployed in more than 85 countries, as well as a library of more than 800 evaluations and instruments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt also provides a skilled team and an end-to-end patient-centred technology platform to CRO partners to enhance market impact.
Extending scientific capabilities and support to assess protocols, as well as align complete and fit-for-purpose technology is crucial to the partner programme.
The programme also delivers in-depth training and the deployment of technology empowerment to permit quick and dynamic clinical trial configuration using a subscription licence model.
The latest development comes after the company unveiled a configurable electronic clinical outcomes assessment (eCOA) technology.
This technology is driven by outcomes science capabilities across various therapeutic areas and guarantees rapid trial deployment and data quality.
It can also provide enhanced patient engagement and compliance across all levels of protocol endpoint complexity.
